CanWell’s TLR7 Agonist CAN1012 IND Granted Approval by US FDA
CanWell Pharma announced that its First-in-Class innovative drug, TLR7 agonist CAN1012, has been granted clinical approval by the US Food and Drug Administration (FDA) and will soon conduct Phase I…
Professor Qiang Pan-Hammarström Named Member of Scientific Advisory Board at CanWell
CanWell announced today that Professor Qiang Pan-Hammarström has joined the Scientific Advisory Board (SAB) at CanWell. Professor Pan-Hammarström is a leading researcher in studying the genetic mechanisms and treatment of…
CanWell submits to US FDA the Investigational New Drug (IND) for its TLR7 agonist CAN1012 for Cancer Treatment
CanWell Pharma announced today that its independently developed First-in-Class innovative drug, TLR7 agonist, was submitted to the US Food and Drug Administration (FDA) for Investigational New Drug (IND) application and…
Dr. Bernard A. Fox Appointed the Member of Scientific Advisory Committee of CanWell
CanWell announced today that Dr. Bernard A. Fox is appointed as the Advisor of CanWell’s Scientific Advisory Committee (SAC). Dr. Fox is a leading researcher in the field of cancer…
CanWell, Sun Yat-sen Memorial Hospital of Sun Yat-sen University and UbiVac Jointly Held a Clinical Seminar on Cancer Vaccine DPV-001
Sun Yat-sen Memorial Hospital of Sun Yat-sen University, together with CanWell and UbiVac, Inc., successfully held the First-in-Class International Symposium on Clinical Trials of Cancer Vaccine DPV-001 Vaccine. CanWell has…
CanWell and UbiVac Announce Exclusive License Agreement For Cancer Vaccine DPV-001 in Greater China
CanWell Pharma Inc., a leading venture-backed biopharmaceutical company developing innovative immunotherapies for cancer, and UbiVac, Inc., a US clinical stage immunotherapy company, today announced an exclusive license agreement to develop and…